Michael Copeman

The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study

Michael Millward, Colin M. House, David D.L. Bowtell et al. · British Journal of Cancer · 2006 · 53 citations · Full text

Medicine, Oncology, Pharmacology +17

Bisphosphonate infusions: patient preference, safety and clinic use

Boris Chern, David Joseph, D. Joshua et al. · Supportive Care in Cancer · 2004 · 35 citations

Pharmacy, Pharmacotherapy, Parenteral Dosage Forms +9

High Response Rates with the Combination of Bortezomib, Dexamethasone and the Pan-Histone Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma in a Phase I/II Clinical Trial

Simon J. Harrison, Hang Quach, Kally Yuen et al. · Blood · 2008 · 33 citations

Medicine, Pharmacology, Pharmacotherapy +17

Higher-Dose Imatinib (600 mg/Day) with Selective Intensification in Newly Diagnosed CML Patients in Chronic Phase; Cytogenetic Response Rates at 12 Months Are Superior to IRIS.

Timothy P. Hughes, Susan Branford, John Reynolds et al. · Blood · 2004 · 24 citations

Life Sciences, Pharmacotherapy, Cytogenetics +6

Safety and Efficacy of the Combination of Bortezomib with the Deacetylase Inhibitor Romidepsin in Patients with Relapsed or Refractory Multiple Myeloma: Preliminary Results of a Phase I Trial.

Miles Prince, Hang Quach, Paul J. Neeson et al. · Blood · 2007 · 17 citations

Medicine, Oncology, Pharmacology +15